Sven Ante Lundberg's Insider Trades & SAST Disclosures
Sven Ante Lundberg's most recent trade in Merus N.V was a trade of 40,601 Common Shares done . Disclosure was reported to the exchange on Feb. 19, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Sven Ante Lundberg.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Feb 2025 | 40,601 | 40,601 (0%) | 0% | 0 | Common Shares | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Gift of securities by or to the insider at price $ 0.00 per share. | 19 Feb 2025 | 40,601 | 0 (0%) | 0% | 0 | Common Shares | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 24.43 per share. | 13 Feb 2025 | 16,372 | 40,601 (0%) | 0% | 24.4 | 399,968 | Common Shares |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Feb 2025 | 16,372 | 351,628 | - | - | Share Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 29 Jan 2025 | 300,000 | 300,000 | - | - | Share Option (right to buy) | |
| Vor Biopharma Inc | Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 23 May 2024 | 30,000 | 30,000 | - | - | Stock Option (Right to Buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PEO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 07 May 2024 | 360,000 | 360,000 | - | - | Share Option (right to buy) | |
| Vor Biopharma Inc | Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 May 2023 | 30,000 | 30,000 | - | - | Stock Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Feb 2023 | 380,000 | 380,000 | - | - | Share Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Purchase of securities on an exchange or from another person at price $ 14.38 per share. | 03 Nov 2022 | 14,706 | 40,576 (0%) | 0% | 14.4 | 211,431 | Common Shares |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Purchase of securities on an exchange or from another person at price $ 22.99 per share. | 19 Aug 2022 | 704 | 20,044 (0%) | 0% | 23.0 | 16,187 | Common Stock |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Purchase of securities on an exchange or from another person at price $ 22.97 per share. | 12 Jul 2022 | 4,340 | 19,340 (0%) | 0% | 23.0 | 99,685 | Common Shares |
| Vor Biopharma Inc | Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Jun 2022 | 16,911 | 16,911 | - | - | Stock Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 31 Jan 2022 | 295,000 | 295,000 | - | - | Share Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2021 | 12,627 | 339,120 | - | - | Share Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 13.52 per share. | 02 Aug 2021 | 12,627 | 12,627 (0%) | 0% | 13.5 | 170,717 | Common Shares |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 12.54 per share. | 02 Aug 2021 | 2,373 | 15,000 (0%) | 0% | 12.5 | 29,757 | Common Shares |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 02 Aug 2021 | 2,373 | 3,797 | - | - | Share Option (right to buy) | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Gift of securities by or to the insider at price $ 0.00 per share. | 25 Mar 2021 | 74,000 | 0 (0%) | 0% | 0 | Common Shares | |
| Merus N.V | Sven Ante Lundberg | Director, President, CEO & PFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Feb 2021 | 368,000 | 368,000 | - | - | Share Option (right to buy) | |
| Vor Biopharma Inc | Sven Ante Lundberg | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Feb 2021 | 16,900 | 16,900 | - | - | Stock Option (right to buy) |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges